Photo: infusion bag and monitor

NICE reject ocrelizumab for primary progressive MS

Ocrelizumab (brand name Ocrevus) is currently available to treat people with relapsing MS in England and Wales. However, the National Institute for Health and Care Excellence (NICE) announced this morning it won't make the treatment available for primary progressive MS.

Why have NICE said no to ocrelizumab?

NICE say ocrelizumab costs too much for the benefits it can provide. In medical trials of the drug, people with primary progressive MS saw an average drop of around 25% in the risk of their disability getting worse.

Campaigner Holly, who has primary progressive MS says the decision is simply wrong.

Pod image
Ocrelizumab could help slow down my MS and give me back control of my future. This decision is simply wrong. I don’t have any other treatment options. Holly, campaigner with primary progressive MS

Right now, this decision affects England and Wales. But getting the right deal is crucial to make sure ocrelizumab can go through approval processes in the other nations in the UK without unnecessary delays.

Tweet your MP to show up for ocrelizumab

Or if you're not on twitter, email them to ask for their support.

Drug manufacturer offers lower price

Roche, the company that makes ocrelizumab have offered a lower price, but NICE are not allowed to accept a different price from what they pay for it to treat relapsing MS. Roche have called for NICE to be allowed to consider their lower price and hope a solution can be reached.

What can we do to reverse this decision?

We’re calling for NICE, Roche and NHS England to put patients first and agree a deal to make ocrelizumab available at a price the NHS can afford. We've made a petition so we can all speak up together. It will be open for two weeks.

Our Director of External Affairs, Genevieve Edwards, says:

This is a deeply disappointing decision, denying many desperate people access to a treatment which may slow down their disability progression.

"MS can be painful and often exhausting. For many people living with primary progressive MS – who have no NHS treatment options – ocrelizumab offered them a shot at a better future.

21,000 spoke up for ocrelizumab, now MPs must help

In September this year, over 21,000 of us spoke up together to call for NICE, NHS England and the drug manufacturer Roche to find a deal together.

Now we need support from Westminster to help keep up the pressure. We've organised an event in the Houses of Parliament on Monday 26 November. It's 2-4pm in the Jubilee Room and we need all our MPs to attend and speak up for ocrelizumab for progressive MS.

Tweet your MP to show up for ocrelizumab

Or if you're not on twitter, email them to ask for their support.

The next research breakthrough is in reach

Your donation will help stop MS.

  • Please enter an amount

    Our minimum donation is £2, please enter a different amount.

£30could process one blood sample, giving researchers crucial information about genes and the immune system.

£50could pay for an hour on a microscope, so scientists can study cells and tissue in greater detail and improve their understanding of the biology of MS.

£100could pay for half an hour of MRI use, so researchers can monitor the success of clinical trials and understand MS in more detail.

Every penny you give really does take us a step closer to stopping MS. Your donation will make a difference.

  • Please enter an amount

    Our minimum donation is £2, please enter a different amount.

£10a month could pay for lab equipment like microscope slides to study the building blocks of MS

£20a month could pay for lab equipment like petri dishes to grow bacteria important for studying genetics

£30a month could process a blood sample to help us understand what causes MS, so we can stop it in its tracks

Your regular donation means we can keep funding world class MS research with confidence. Together we will stop MS.

MS researcher at work in lab, using a pipette